Enzon Pharmaceuticals, Inc.
ENZN
$0.0998
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 26.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 26.00K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | -- | 26.00K | -- | -- |
| SG&A Expenses | 325.00K | 351.00K | 351.00K | 326.00K | 216.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 325.00K | 351.00K | 351.00K | 326.00K | 216.00K |
| Operating Income | -325.00K | -351.00K | -325.00K | -326.00K | -216.00K |
| Income Before Tax | 221.00K | 303.00K | 280.00K | 321.00K | 423.00K |
| Income Tax Expenses | 293.00K | 49.00K | 4.00K | 1.00K | -249.00K |
| Earnings from Continuing Operations | -72.00K | 254.00K | 276.00K | 320.00K | 672.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.00K | 254.00K | 276.00K | 320.00K | 672.00K |
| EBIT | -325.00K | -351.00K | -325.00K | -326.00K | -216.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 74.22M | 74.22M | 74.22M | 74.22M | 74.22M |
| Average Diluted Shares Outstanding | 74.22M | 74.22M | 74.22M | 74.22M | 74.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | 0.00% | 0.00% | 398.44% | 0.00% |